These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 37456816)

  • 1. Inflammation as a therapeutic target in heart failure with preserved ejection fraction.
    Peh ZH; Dihoum A; Hutton D; Arthur JSC; Rena G; Khan F; Lang CC; Mordi IR
    Front Cardiovasc Med; 2023; 10():1125687. PubMed ID: 37456816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.
    Patel RB; Shah SJ
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():41-63. PubMed ID: 30296895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models.
    van Ham WB; Kessler EL; Oerlemans MIFJ; Handoko ML; Sluijter JPG; van Veen TAB; den Ruijter HM; de Jager SCA
    JACC Basic Transl Sci; 2022 Aug; 7(8):844-857. PubMed ID: 36061340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic benefit of early diagnosis with exercise stress testing in heart failure with preserved ejection fraction.
    Saito Y; Obokata M; Harada T; Kagami K; Wada N; Okumura Y; Ishii H
    Eur J Prev Cardiol; 2023 Jul; 30(9):902-911. PubMed ID: 37094815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.
    Çavuşoğlu Y; Çelik A; Altay H; Nalbantgil S; Özden Ö; Temizhan A; Ural D; Ünlü S; Yılmaz MB; Zoghi M
    Turk Kardiyol Dern Ars; 2022 May; 50(Supp1):S1-S34. PubMed ID: 35969235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Heart Failure with Preserved Ejection Fraction.
    Ilieșiu AM; Hodorogea AS
    Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Failure with Preserved Ejection Fraction-a Concise Review.
    Adamczak DM; Oduah MT; Kiebalo T; Nartowicz S; Bęben M; Pochylski M; Ciepłucha A; Gwizdała A; Lesiak M; Straburzyńska-Migaj E
    Curr Cardiol Rep; 2020 Jul; 22(9):82. PubMed ID: 32648130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.
    D'Assante R; Arcopinto M; Rengo G; Salzano A; Walser M; Gambino G; Monti MG; Bencivenga L; Marra AM; Åberg DN; De Vincentiis C; Ballotta A; Bossone E; Isgaard J; Cittadini A
    ESC Heart Fail; 2021 Apr; 8(2):1681-1686. PubMed ID: 33512777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population.
    Chia YC; Kieneker LM; van Hassel G; Binnenmars SH; Nolte IM; van Zanden JJ; van der Meer P; Navis G; Voors AA; Bakker SJL; De Borst MH; Eisenga MF
    J Am Heart Assoc; 2021 Jun; 10(11):e018549. PubMed ID: 33998283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches.
    Toth PP; Gauthier D
    Postgrad Med; 2021 Mar; 133(2):125-139. PubMed ID: 33283589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
    Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
    ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.
    Bilak JM; Alam U; Miller CA; McCann GP; Arnold JR; Kanagala P
    Card Fail Rev; 2022 Jan; 8():e24. PubMed ID: 35846985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study.
    Eidizadeh A; Schnelle M; Leha A; Edelmann F; Nolte K; Werhahn SM; Binder L; Wachter R
    ESC Heart Fail; 2023 Feb; 10(1):200-210. PubMed ID: 36184749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HEART Camp Exercise Intervention Improves Exercise Adherence, Physical Function, and Patient-Reported Outcomes in Adults With Preserved Ejection Fraction Heart Failure.
    Alonso WW; Kupzyk KA; Norman JF; Lundgren SW; Fisher A; Lindsey ML; Keteyian SJ; Pozehl BJ
    J Card Fail; 2022 Mar; 28(3):431-442. PubMed ID: 34534664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
    Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathophysiology of heart failure with preserved ejection fraction and its therapeutic implications.
    Fontes-Carvalho R; Leite-Moreira A
    Rev Port Cardiol; 2009 Jan; 28(1):63-82. PubMed ID: 19388494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation in HFpEF: Key or circumstantial?
    van Empel V; Brunner-La Rocca HP
    Int J Cardiol; 2015; 189():259-63. PubMed ID: 25897922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
    Wintrich J; Kindermann I; Ukena C; Selejan S; Werner C; Maack C; Laufs U; Tschöpe C; Anker SD; Lam CSP; Voors AA; Böhm M
    Clin Res Cardiol; 2020 Sep; 109(9):1079-1098. PubMed ID: 32236720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.